New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
09:25 EDTBLUE, BLUE, CELG, CELG, NVS, NVSPiper Jaffray biopharm analyst holds an analyst/industry conference call
Biopharmaceuticals Analyst Schimmer reviews major CAR-T programs in development, explains fundamentals of CAR-T and TCR-T and compares clinical data of CAR-T trials on an Analyst/Industry conference call. Relevant companies BLUE, CELG and NVS may be included on the Analyst/Industry conference call to be held on June 19 at 10 am.
News For BLUE;CELG;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
October 1, 2015
07:37 EDTNVSXOMA announces agreement for anti-TGFb program with Novartis
Subscribe for More Information
07:31 EDTBLUELeerink to hold a roundtable
Subscribe for More Information
06:28 EDTCELGPiper sees 'highly compelling' entry points in large cap biopharma
Piper Jaffray analyst Joshua Schimmer says recent weakness in the biopharma sector has created a "valuation discrepancy" versus non-growth peers that he hasn't seen for a number of years. The sector remains in a "prolonged growth cycle" driven by extended product cycles, attractive and improving pipelines and M&A opportunities, Schimmer tells investors in a research note titled "Out of The Ashes, A Growth Sector Poised To Fly Higher." He expects large-cap biopharma companies to lift the sector out of the recent weakness. His preferred growth names include Celgene (CELG), Alexion (ALXN), Amgen (AMGN) and Endo (ENDP).
05:47 EDTCELGCelgene upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov upgraded Celgene to Overweight citing an "increasingly attractive" valuation following the recent pullback in shares. The company is one the "most fundamentally sound biotechs" and shares at current levels are "too compelling to remain on the sidelines," Kasimov tells investors in a research note. He keeps a $152 price target for the stock. Celgene closed yesterday up $2.79 to $108.13. Shares are down 8% over the past month.
September 30, 2015
17:04 EDTNVSNovartis says results of Phase 3 study of secukinumab met endpoints
Subscribe for More Information
September 29, 2015
12:35 EDTNVSPerrigo shareholders pressure company to explore sale, Reuters says
Certain Perrigo (PRGO) shareholders have requested that company explore a sale, hoping for an alternative to Mylan's (MYL) approximately $25B hostile bid, Reuters reports, citing people familiar with the matter. The pressure represents a challenge to Perrigo's defense strategy, the report says. Some of the company's shareholders view Novartis (NVS), Sanofi (SNY), Procter & Gamble (PG), and Colgate-Palmolive (CL) as potential suitors, the report says. Reference Link
11:11 EDTCELGStocks with call strike movement; CELG GILD
Subscribe for More Information
08:46 EDTNVSNoven reports final decisions in IPRs challenging Novartis' Exelon patch patents
Subscribe for More Information
08:33 EDTBLUEAlexandria Real Estate announces bluebird bio executed lease
Alexandria Real Estate (ARE) Equities announced that bluebird bio (BLUE) executed a 10-year lease for approximately 253,000 rentable square feet at 60 Binney Street at the Alexandria Center at Kendall Square campus. The lease encompasses the entire 60 Binney Street building with the exception of a ground-floor retail suite. With the relocation of its headquarters to 60 Binney Street, bluebird bio, a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, will be expanding its presence in Cambridge to support the company's continued growth. The 60 Binney Street project, which is targeting LEED Gold Certification, is expected to be delivered in late 2016.
September 28, 2015
12:22 EDTNVSArray says binimetinib-encorafenib combo shows differentiated tolerability
Subscribe for More Information
07:58 EDTNVSNovartis to hold a conference call
Subscribe for More Information
September 27, 2015
18:48 EDTNVSNovartis reports updated Phase 3 data on Tafinlar-Mekinist for melanoma
Subscribe for More Information
16:16 EDTNVSNovartis reports Phase 3 reults on Afinitor for neuroendocrine tumors
Novartis announced results of a Phase 3 pivotal study showing Afinitor, or everolimus, tablets reduced the risk of progression by 52% versus placebo in patients with advanced, progressive, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin. Additionally, the data show everolimus, a mammalian target of rapamycin inhibitor, extended median progression free survival by 7.1 months. Median PFS by central review was 11 months in the everolimus arm and 3.9 months in the placebo arm. Overall survival was a key secondary endpoint of the trial. While the OS data are not mature, the first interim analysis showed a trend favoring the everolimus arm, according to Novartis. Additional analyses are planned. Another secondary endpoint was best overall response rate. The study found that 64% of patients receiving everolimus experienced at least some degree of tumor shrinkage compared to 26% of those on placebo. Adverse events were consistent with the known safety profile of everolimus. The results of the RADIANT-4 study will serve as the basis of worldwide regulatory submissions for Afinitor for the treatment of advanced, progressive, nonfunctional GI and lung NET, Novartis said.
September 25, 2015
16:17 EDTCELGOn The Fly: Top stock stories for Friday
Stocks opened with sharp gains the day after Fed Chair Janet Yellen gave some clarity to the market by suggesting the Fed will most likely raise interest rates by the end of the year. During afternoon trading, the news flow slowed and the volume lightened on the buy side, leaving the sellers with the upper hand. The Nasdaq was the first index to move into negative territory, led by broad weakness in biotech stocks, while the Dow was helped to stay in the green by a big post-earnings move higher in Nike (NKE). The averages limped into the close, leaving the market with an interesting set-up to begin next week. Outside of stock news, it was certainly a headline packed day, as Speaker of the House John Boehner announced that he will resign at the end of October, Chinese President Xi Jinping continued his U.S. visit and Pope Francis addressed the United Nations while spending a second day in New York City. ECONOMIC EVENTS: In the U.S., the third estimate of second quarter GDP showed the economy grew 3.9% quarter-over-quarter, versus expectations for the GDP growth estimate to stay at 3.7%. Personal consumption in Q2 is now believed to have grown 3.6%, up from the prior estimate of 3.1%. The final University of Michigan consumer sentiment reading for September came in at 87.2, which was down from August's 91.9 but above the expected 86.2 reading... Federal Reserve Chair Janet Yellen said during a speech at UMass Amherst last night that the central bank remains inclined to hike rates this year. Yellen's remarks were incrementally hawkish, but welcomed by the market, since they helped clarify the message the Fed delivered a week ago. Of note, the Fed chair paused multiple times toward the end of her speech and received medical attention afterward, but returned to her regular schedule later in the evening, with the bank explaining that Yellen was dehydrated after a long day but was otherwise fine. COMPANY NEWS: Nike jumped $10.23, or 8.9%, to $125.02 after Thursday night's report of better than expected earnings and futures orders prompted numerous price target hikes at Street research firms. Additionally, Sterne Agee upgraded Nike to Buy from Neutral, saying it thinks the company is benefiting from its "global grass roots engagement with its customers," which enables it to meet its customers' needs and determine to what extent it can raise prices. The firm, which thinks that the company is continuing to gain share, has a $150 price target on the athletic gear giant... Biotech stocks, which were already having a bad week, ended the week on a down note, as the iShares NASDAQ Biotechnology Index (IBB) fell 4.9%, giving it a weekly decline of about 13%. Among the biggest large-cap losers in the space were Vertex (VRTX), which fell 7%, Regeneron (REGN), which dropped 6% and Celgene (CELG), which slid 4.8%. MAJOR MOVERS: Among the notable gainers was Jabil Circuit (JBL), which advanced $2.38, or 12.2%, to $21.88 after it reported higher than expected earnings and gave guidance for its November quarter that was significantly above expectations. Also higher was Cirrus Logic (CRUS), which gained $3.90, or 14.4%, to $31.03 after tear downs of Apple's (AAPL) iPhone 6S and 6S Plus led analysts to conclude that the chipmaker appears poised to obtain more revenue from the new devices than from the previous generation of the market-leading smartphone. Among the noteworthy losers was Finish Line (FINL), which fell $4.86, or 19.6%, to $19.91 after reporting second quarter revenue that missed expectations and saying it expects adjusted earnings this fiscal year to increase in a low single to mid single digits percentage from last year. Also lower following its earnings report was smartphone and software maker BlackBerry (BBRY), which slid 7.68% to $6.49 after the company posted a second quarter loss that was steeper than analysts expected. BlackBerry also confirmed press reports that it plans to launch a new phone that uses Google's (GOOG) Android operating system instead of its own proprietary BB10 OS. Shares of Aratana Therapeutics (PETX), which dropped $6.81, or 38.97%, to $10.68 after the company said that, based on "mixed clinical and scientific results," it does not believe that canine lymphoma products AT-004 and AT-005 in their current, first-generation forms will capture the desired lymphoma market opportunity. INDEXES: The Dow rose 113.35, or 0.7%, to 16,314.67, the Nasdaq fell 47.98, or 1.01%, to 4,686.50, and the S&P 500 added/slipped 0.90, or 0.05%, to 1,931.34.
11:35 EDTBLUEbluebird bio management to meet with Maxim
5:30 pm Cocktails, followed by 6pm Group dinner with management will be held in New York on September 30 hosted by Maxim.
07:22 EDTNVS, CELGEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
05:21 EDTCELGCelgene's VIDAZA receives positive CHMP opinion
Subscribe for More Information
05:15 EDTNVSNovartis announces CHMP adopted positive opinion for Entresto
Subscribe for More Information
September 24, 2015
18:38 EDTNVSNovartis CEO discusses drug pricing, paying doctors, Washington Post reports
Novartis CEO Joseph Jimenez said in an interview with the Washington Post, "Drug pricing is a very complicated topic because we invest in high-risk activity... So when we price a drug, we price it based on the value it will bring into that marketplace, and also how its price compares to the other therapies currently on the market. There's been a lot of discussion about drug pricing. What we have to do is we have to shift that conversation away from the price toward the value. Like, what exactly is the value of this drug that is going to result in a positive outcome? And is society willing to pay for that drug? At Novartis, we take a little bit of a different approach than our peers. Not only are we a large, innovative drug manufacturer, but we also are the second largest generics manufacturer... I also believe at Novartis that the day that patents expire, it's our obligation to offer a low-cost version in a generic form." Discussing the practice of drug companies paying doctors to prescribe particular drugs, Jiminez said, "It's unfortunate, because that's a situation where society's expectations have changed to the point where even doing what's legal is not doing what's right. What we have to do is, we have to find new ways to educate physicians about our new drugs... We're looking at ways digitally to communicate with physicians and at some new tools, so we can stay ahead of the curve. So rather than wait for regulations to change, Novartis can step back and say, 'We're going to do what society would expect us to do, not just do what's legal.'" Reference Link
09:07 EDTNVSUnilife ammends clinical supply agreement with Novartis
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use